The Board of Directors of Earkart Limited , at their meeting held on 29 May 2026, approved the incorporation of two wholly-owned subsidiaries (WOS)—Earkart Pharmaceuticals Private Limited and Earkart Healthcare Services Private Limited. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of the said regulations. The intimation was filed from Noida and signed by Preeti Srivastava, Company Secretary & Compliance Officer (Membership No: A31615).

Key Details of the Proposed Subsidiaries

Both proposed entities are yet to be incorporated and will, upon incorporation, become wholly-owned subsidiaries and related parties of Earkart Limited and its other subsidiaries. The promoters, promoter group, and group companies have no interest in the proposed entities beyond what is stated above. The following table summarises the key parameters for each proposed WOS:

Business Objectives of the Proposed Entities

The two subsidiaries have been proposed with distinct operational mandates within the broader healthcare space:

• Earkart Pharmaceuticals Private Limited is being incorporated to manufacture, promote, sell, and distribute pharmaceuticals and other related products.
• Earkart Healthcare Services Private Limited is being incorporated to provide services in the healthcare sector.

Regulatory Compliance and Disclosure

The intimation was made in compliance with Regulation 30 and Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and in accordance with circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30 January 2026. No governmental or regulatory approvals are required for the incorporation of either proposed subsidiary. The company has stated that further details will be made available on its website at https://www.earkart.in .

Earkart Limited reported a 25.4% increase in revenue from operations to ₹540,352.97 thousand for the financial year ended March 31, 2026, while net profit for the year declined by 28.4% to ₹49,323.01 thousand. The statutory auditor, M/s Timsi & Associates, issued an Audit Report with an unmodified opinion on the audited financial results for the half year and year ended March 31, 2026. The board approved the audited standalone financial results during a meeting held on May 29, 2026.

The company's total income for FY26 stood at ₹541,417.52 thousand, compared to ₹431,920.64 thousand in the previous year. Total expenses for the period rose to ₹468,861.50 thousand from ₹341,764.02 thousand in FY25. For the half-year ended March 31, 2026, the company recorded a profit after tax of ₹30,789.99 thousand on a total income of ₹318,316.21 thousand. Earnings per share (EPS) for the year stood at ₹3.99, down from ₹6.59 in the previous year.

The board also appointed M/s Arvind Aggarwal & Associates, Chartered Accountants, as the Internal Auditor and M/s Nikita Kothari & Associates, Practicing Company Secretary, as the Secretarial Auditor for the financial year 2026-27. These appointments were made to comply with Section 138 of the Companies Act, 2013, and applicable SEBI regulations. The trading window for dealing in the company's listed securities, which was closed until May 31, 2026, has now concluded as per the company's Code of Conduct for the Prevention of Insider Trading.

The balance sheet as of March 31, 2026, shows total assets of ₹694,918.90 thousand, a significant increase from ₹302,443.75 thousand in the previous year, driven largely by a rise in cash and cash equivalents to ₹216,867.38 thousand. Shareholders' funds also improved to ₹643,451.84 thousand, comprising share capital of ₹137,539.32 thousand and reserves and surplus of ₹505,912.52 thousand.